Skip Navigation


Rheumatology Advance Access originally published online on October 15, 2009
Rheumatology 2009 48(12):1620; doi:10.1093/rheumatology/kep317
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/12/1620    most recent
kep317v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dervieux, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dervieux, T.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability: reply

Thierry Dervieux1

1Cypress Bioscience, San Diego, CA, USA

Correspondence to: Cypress Bioscience, 9393 Towne Ctr Drive, San Diego CA, 92 121, USA. E-mail: tdervieux@cypressbio.com

The first 10% of the full text of this article appears below.

SIR, We should thank Barretta and colleagues [1] for bringing to our attention the recent and somewhat severe criticism of the false positive report probability (FPRP) method . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?